KEGG   DRUG: D09587Help
Entry
D09587                      Drug                                   

Name
Brentuximab vedotin (genetical recombination) (JAN);
Brentuximab vedotin (USAN);
Adcetris (TN)
Product
Formula
C6476H9930N1690O2030S40. (C68H105N11O15)n
Sequence
  Type
Peptide
Activity
Treatment of Hodgkin's lymphoma, CD30-positive hematologic malignancies [DS:H00007]
Remark
Therapeutic category: 
ATC code: 
Comment
CD30-directed antibody-drug conjugate to Monomathyl auristatin E [DR:D09691]
monoclonal antibody
Target
CD30 [HSA:943] [KO:K05145]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction  
 
Interaction
Genomic biomarker: CD30 [HSA:943]
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC12 Brentuximab vedotin
      D09587  Brentuximab vedotin (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09587  Brentuximab vedotin (genetical recombination) (JAN); Brentuximab vedotin (USAN)
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  TNF receptor family
   TNFRSF8 (CD30)
    Brentuximab vedotin
     D09587  Brentuximab vedotin (USAN)
Antineoplastics [BR:br08308]
 Molecularly targeted agents
  Monoclonal antibody
   Brentuximab
    D09587  Brentuximab vedotin (USAN)
BRITE hierarchy
Other DBs
CAS: 
914088-09-8
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system